Related Articles
Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes
In vitro alterations in fecal short chain fatty acids and organic anions induced by the destruction of intestinal microflora under hypotonic and aerobic conditions
Non‑alcoholic fatty liver disease: A major challenge in type 2 diabetes mellitus (Review)
Inhibition of CCL19 benefits non‑alcoholic fatty liver disease by inhibiting TLR4/NF‑κB‑p65 signaling
Non-B, non-C hepatocellular carcinoma (Review)